These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1497648)

  • 1. Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme.
    Pollock DM; Shiosaki K; Sullivan GM; Opgenorth TJ
    Biochem Biophys Res Commun; 1992 Jul; 186(2):1146-50. PubMed ID: 1497648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats.
    McMahon EG; Palomo MA; Brown MA; Bertenshaw SR; Carter JS
    Am J Hypertens; 1993 Aug; 6(8):667-73. PubMed ID: 8217029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats.
    McMahon EG; Palomo MA; Moore WM
    J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S29-33. PubMed ID: 1725358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure activity relationship of phosphoramidon derivatives for in vivo endothelin-converting-enzyme inhibition.
    Bigaud M; Hauss B; Schalk C; Jauch MF; D'Orchymont H
    Fundam Clin Pharmacol; 1994; 8(2):155-61. PubMed ID: 8020872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diuretic-natriuretic actions and pressor effects of big-endothelin (1-39) in phosphoramidon-treated rats.
    Hoffman A; Haramati A; Dalal I; Shuranyi E; Winaver J
    Proc Soc Exp Biol Med; 1994 Feb; 205(2):168-73. PubMed ID: 8108467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in potency of big endothelin-1-induced pressor action in rat isolated perfused mesenteric artery, hindquarter and lung.
    Hisaki K; Matsumura Y; Fujita K; Maekawa H; Takaoka M; Morimoto S
    Life Sci; 1994; 54(4):275-80. PubMed ID: 8289588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys.
    Verbeuren TJ; Mennecier P; Merceron D; Simonet S; de Nanteuil G; Vincent M; Laubie M
    J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S81-4. PubMed ID: 7510006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S 17162 is a novel selective inhibitor of big ET-1 responses in the rat.
    Descombes JJ; Mennecier P; Versluys D; Barou V; de Nanteuil G; Laubie M; Verbeuren TJ
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S61-4. PubMed ID: 8587469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of metalloprotease inhibitors on smooth muscle endothelin-converting enzyme activity.
    Balwierczak JL; Kukkola PJ; Savage P; Jeng AY
    Biochem Pharmacol; 1995 Jan; 49(3):291-6. PubMed ID: 7857315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-converting enzyme and its in vitro and in vivo inhibition.
    Yano M; Okada K; Takada J; Hioki Y; Matsuyama K; Fukuroda T; Noguchi K; Nishikibe M; Ikemoto F
    J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S26-8. PubMed ID: 1725349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats.
    Gratton JP; Maurice MC; Rae GA; D'Orléans-Juste P
    Am J Hypertens; 1995 Nov; 8(11):1121-7. PubMed ID: 8554736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic evidence for the specificity of the phosphoramidon-sensitive endothelin-converting enzyme for big endothelin-1.
    Télémaque S; Gratton JP; Claing A; D'Orléans-Juste P
    J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S85-9. PubMed ID: 7510007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different pressor and bronchoconstrictor properties of human big-endothelin-1, 2 (1-38) and 3 in ketamine/xylazine-anaesthetized guinea-pigs.
    Gratton JP; Rae GA; Claing A; Télémaque S; D'Orléans-Juste P
    Br J Pharmacol; 1995 Feb; 114(3):720-6. PubMed ID: 7735698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1.
    Matsumura Y; Hisaki K; Takaoka M; Morimoto S
    Eur J Pharmacol; 1990 Aug; 185(1):103-6. PubMed ID: 2226629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of phosphoramidon on endothelin-1 and big endothelin-1 production in human aortic endothelial cells.
    Matsumura Y; Tsukahara Y; Kojima T; Murata S; Murakami A; Takada K; Takaoka M; Morimoto S
    Biol Pharm Bull; 1995 Mar; 18(3):401-6. PubMed ID: 7550091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1.
    Trapani AJ; Balwierczak JL; Lappe RW; Stanton JL; Graybill SC; Hopkins MF; Savage P; Sperbeck DM; Jeng AY
    Biochem Mol Biol Int; 1993 Dec; 31(5):861-7. PubMed ID: 8136704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme.
    Hisaki K; Matsumura Y; Maekawa H; Fujita K; Takaoka M; Morimoto S
    Am J Physiol; 1994 Feb; 266(2 Pt 2):H422-8. PubMed ID: 8141343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
    Yap EY; Battistini B; McKay KO
    Br J Pharmacol; 2000 Jan; 129(1):170-6. PubMed ID: 10694217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1.
    D'Orléans-Juste P; Lidbury PS; Telemaque S; Warner TD; Vane JR
    J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S251-5. PubMed ID: 1725347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro.
    D'Orléans-Juste P; Télémaque S; Claing A
    Br J Pharmacol; 1991 Oct; 104(2):440-4. PubMed ID: 1797310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.